<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p25" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_25{left:130px;bottom:1195px;letter-spacing:0.2px;}
#t2_25{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_25{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_25{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_25{left:525px;bottom:1096px;letter-spacing:-0.01px;}
#t6_25{left:238px;bottom:1076px;letter-spacing:-0.01px;}
#t7_25{left:238px;bottom:1057px;letter-spacing:-0.01px;}
#t8_25{left:238px;bottom:1037px;letter-spacing:-0.01px;}
#t9_25{left:238px;bottom:1018px;letter-spacing:-0.01px;}
#ta_25{left:238px;bottom:999px;letter-spacing:-0.01px;}
#tb_25{left:238px;bottom:925px;letter-spacing:-0.01px;}
#tc_25{left:238px;bottom:906px;letter-spacing:-0.01px;}
#td_25{left:238px;bottom:886px;letter-spacing:-0.01px;}
#te_25{left:238px;bottom:867px;letter-spacing:-0.01px;}
#tf_25{left:238px;bottom:847px;letter-spacing:-0.01px;}
#tg_25{left:238px;bottom:828px;letter-spacing:-0.01px;}
#th_25{left:238px;bottom:808px;letter-spacing:-0.01px;}
#ti_25{left:238px;bottom:735px;letter-spacing:-0.01px;}
#tj_25{left:238px;bottom:715px;letter-spacing:-0.01px;}
#tk_25{left:238px;bottom:696px;letter-spacing:-0.01px;}
#tl_25{left:238px;bottom:677px;letter-spacing:-0.01px;}
#tm_25{left:238px;bottom:657px;letter-spacing:-0.01px;}
#tn_25{left:238px;bottom:638px;letter-spacing:-0.01px;}
#to_25{left:238px;bottom:584px;letter-spacing:-0.01px;}
#tp_25{left:238px;bottom:564px;letter-spacing:-0.01px;}
#tq_25{left:238px;bottom:545px;letter-spacing:-0.01px;}
#tr_25{left:238px;bottom:525px;letter-spacing:-0.01px;}
#ts_25{left:238px;bottom:506px;letter-spacing:-0.01px;}
#tt_25{left:238px;bottom:486px;letter-spacing:-0.01px;}
#tu_25{left:238px;bottom:432px;letter-spacing:-0.01px;}
#tv_25{left:238px;bottom:413px;letter-spacing:-0.01px;}
#tw_25{left:238px;bottom:393px;letter-spacing:-0.01px;}
#tx_25{left:238px;bottom:374px;letter-spacing:-0.01px;}
#ty_25{left:238px;bottom:354px;letter-spacing:-0.01px;}
#tz_25{left:238px;bottom:335px;letter-spacing:-0.01px;}
#t10_25{left:238px;bottom:316px;letter-spacing:-0.01px;}
#t11_25{left:238px;bottom:261px;letter-spacing:-0.01px;}
#t12_25{left:238px;bottom:242px;letter-spacing:-0.01px;}
#t13_25{left:238px;bottom:223px;letter-spacing:-0.01px;}
#t14_25{left:238px;bottom:203px;letter-spacing:-0.01px;}
#t15_25{left:238px;bottom:184px;letter-spacing:-0.01px;}
#t16_25{left:238px;bottom:164px;letter-spacing:-0.01px;}
#t17_25{left:238px;bottom:145px;letter-spacing:-0.01px;}
#t18_25{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_25{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_25{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_25{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_25{font-size:13px;font-family:NotoSans-Regular_7j-_1;color:#000;}
.s4_25{font-size:11px;font-family:NotoSans-Regular_7j-_1;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts25" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

@font-face {
	font-family: NotoSans-Regular_7j-_1;
	src: url("fonts/NotoSans-Regular_7j-_1.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg25Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg25" style="-webkit-user-select: none;"><object width="908" height="1286" data="25/25.svg" type="image/svg+xml" id="pdf25" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_25" class="t s0_25">3.2. Risk factors </span><span id="t2_25" class="t s1_25">25 </span>
<span id="t3_25" class="t s2_25">The current WHO classification now uses the term dysplasia for this group of lesions again [47, </span>
<span id="t4_25" class="t s2_25">48]. A distinction is made between “low-grade” </span><span id="t5_25" class="t s3_25">and “high-grade” dysplasia; carcinoma in situ is </span>
<span id="t6_25" class="t s3_25">a particularly pronounced form of “high-grade” dysplasia and can also be subsumed under this. </span>
<span id="t7_25" class="t s3_25">In German-speaking countries, the somewhat more differentiated three-stage system of low, </span>
<span id="t8_25" class="t s3_25">moderate and high-grade dysplasia is established. Low dysplasia corresponds to a “low grade” </span>
<span id="t9_25" class="t s3_25">lesion, moderate and high-grade dysplasia corresponds to a “high grade” lesion; this </span>
<span id="ta_25" class="t s3_25">classification is also confirmed by data on progression rates [46]. </span>
<span id="tb_25" class="t s3_25">Unfortunately, in the case of head and neck cancer, the concept of squamous intraepithelial </span>
<span id="tc_25" class="t s3_25">neoplasia (SIN), which is better in the opinion of the guideline authors and was also promoted </span>
<span id="td_25" class="t s3_25">in the previous version of the WHO classification and widely used in Germany [49], has not yet </span>
<span id="te_25" class="t s3_25">been finally adopted due to international disputes over the terminology and has now been </span>
<span id="tf_25" class="t s3_25">"replaced" by the old term dysplasia [47, 48]. However, in the opinion of the guideline authors, </span>
<span id="tg_25" class="t s3_25">the term intraepithelial neoplasia is generally preferable to the term epithelial dysplasia, since </span>
<span id="th_25" class="t s3_25">the neoplastic character of the lesions is thus also reflected in the nomenclature. </span>
<span id="ti_25" class="t s3_25">According to the SIN classification, a distinction is made between low-grade, moderate-grade </span>
<span id="tj_25" class="t s3_25">and high-grade squamous intraepithelial neoplasia (SIN) in the laryngeal region [50-52]. In this </span>
<span id="tk_25" class="t s3_25">nomenclature, low-grade dysplasia/squamous intraepithelial neoplasia corresponds to grade </span>
<span id="tl_25" class="t s3_25">SIN I, moderate-grade dysplasia/squamous intraepithelial neoplasia to grade SIN II and high- </span>
<span id="tm_25" class="t s3_25">grade dysplasia/squamous intraepithelial neoplasia to grade SIN III [52], which also includes </span>
<span id="tn_25" class="t s3_25">carcinoma in situ (see above). </span>
<span id="to_25" class="t s3_25">The authors are of the opinion that the SIN classification can still be used analogously to the </span>
<span id="tp_25" class="t s3_25">three-stage dysplasia grading; it seems advisable to specify both terms in the sense of </span>
<span id="tq_25" class="t s3_25">dysplasia/squamous intraepithelial neoplasia including severity (mild/moderate/severe). In </span>
<span id="tr_25" class="t s3_25">addition, for international harmonization and to enable interpretability of future study data, an </span>
<span id="ts_25" class="t s3_25">assessment should be given as to whether this is a "low grade" or "high grade" lesion </span>
<span id="tt_25" class="t s3_25">according to the WHO. </span>
<span id="tu_25" class="t s3_25">The optional separation of the high-grade category into “high-grade dysplasia” and “carcinoma </span>
<span id="tv_25" class="t s3_25">in situ”, which is still proposed in the current WHO, also appears confusing, not useful, not </span>
<span id="tw_25" class="t s3_25">sufficiently supported by data and is not reflected in other organ systems. In the authors’ </span>
<span id="tx_25" class="t s3_25">opinion, it should therefore not be used for the time being. Although the risk of developing an </span>
<span id="ty_25" class="t s3_25">invasive carcinoma increases with higher-grade precursor lesions – regardless of the grading </span>
<span id="tz_25" class="t s3_25">system used – the corresponding figures for quantifying the risk vary greatly between individual </span>
<span id="t10_25" class="t s3_25">studies [46]. </span>
<span id="t11_25" class="t s3_25">From a clinical point of view, leukoplakia must be closely monitored, if necessary also by </span>
<span id="t12_25" class="t s3_25">repeated histological or cytological examinations for possible </span>
<span id="t13_25" class="t s3_25">Transformation tendencies into dysplasia/intraepithelial neoplasia should be monitored, </span>
<span id="t14_25" class="t s3_25">initially an excisional biopsy is indicated wherever possible. In the case of dysplastic lesions, </span>
<span id="t15_25" class="t s3_25">complete removal is recommended. In principle, any lesion that has persisted for more </span>
<span id="t16_25" class="t s3_25">than 3-4 weeks </span>
<span id="t17_25" class="t s3_25">Mucosal changes are suspected of being tumors and must be clarified. </span>
<span id="t18_25" class="t s4_25">© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
